NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $3.06 -0.01 (-0.33%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.06 0.00 (-0.16%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alto Neuroscience Stock (NYSE:ANRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$3.01▼$3.1250-Day Range$2.21▼$3.1152-Week Range$1.60▼$15.04Volume220,948 shsAverage Volume118,220 shsMarket Capitalization$82.83 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingModerate Buy Company Overview Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California. Read More Alto Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreANRO MarketRank™: Alto Neuroscience scored higher than 34% of companies evaluated by MarketBeat, and ranked 704th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingAlto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlto Neuroscience has only been the subject of 2 research reports in the past 90 days.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alto Neuroscience is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alto Neuroscience is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlto Neuroscience has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Alto Neuroscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.54% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 1.99%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.54% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 1.99%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News Sentiment-0.02 News SentimentAlto Neuroscience has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Alto Neuroscience this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address ANRO Stock News HeadlinesSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceAugust 1 at 10:12 AM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANROAugust 1 at 10:00 AM | globenewswire.comJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.August 2 at 2:00 AM | Stansberry Research (Ad)Class Action Filed Against Alto Neuroscience, Inc. (ANRO) Seeking Recovery for Investors - Contact Levi & KorsinskyAugust 1 at 9:00 AM | prnewswire.comShareholders That Lost Money on Alto Neuroscience, Inc. (ANRO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAugust 1 at 2:47 AM | theglobeandmail.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANROJuly 31 at 9:33 PM | globenewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit – ANROJuly 31 at 4:07 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANROJuly 31 at 10:00 AM | prnewswire.comSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $4.23 at the start of the year. Since then, ANRO stock has decreased by 27.7% and is now trading at $3.06. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.06. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share. Who are Alto Neuroscience's major shareholders? Alto Neuroscience's top institutional shareholders include Peapod Lane Capital LLC (1.03%), Y Intercept Hong Kong Ltd (0.14%), Vanguard Personalized Indexing Management LLC (0.06%) and Ground Swell Capital LLC (0.05%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alto Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/13/2025Today8/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Alto Neuroscience$8.50 High Price Target$10.00 Low Price Target$4.00 Potential Upside/Downside+177.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-39.35% Return on Assets-33.86% Debt Debt-to-Equity Ratio0.15 Current Ratio22.53 Quick Ratio22.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.62 per share Price / Book0.54Miscellaneous Outstanding Shares27,070,000Free Float24,059,000Market Cap$82.83 million OptionableN/A Beta1.82 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:ANRO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.